Silke
15.02.2001, 19:00
...auch hier werden die Erwartungen für dieses Quartal erstmal nach unten geschraubt:
HGSI cuts loss, predicts higher R&D
By Ted Griffith, CBS.MarketWatch.com
Last Update: 12:24 PM ET Feb 15, 2001 NewsWatch
Latest headlines
Get Alerted
ROCKVILLE, Md. (CBS.MW) -- Human Genome Sciences narrowed its fourth-quarter net loss as revenue jumped from less than a million dollars to more than $5 million, the biotechnology company reported Thursday.
Today on CBS MarketWatch
Tech stocks steal the show
Ciena blows past profit forecast
Prudential cuts Amazon.com rating to 'sell'
February weakness roils Schwab
Due Diligence: Starbucks as coffee version of McDonald's?
More top stories...
CBS MarketWatch Columns
Updated:
2/15/2001 11:12:58 AM ET
But Human Genome Sciences also said it expects to post a significant loss this year as it ratchets up research and development spending by as much as 70 percent. The Rockville, Md.-based company said it anticipates a 2001 net loss of $70 million to $90 million, or 56 cents to 72 cents per share. Human Genome Sciences (HGSI: news, msgs) was expected to post a loss of 44 cents per share in 2001, according to the average estimate of analysts polled by First Call/Thomson Financial.
Human Genome Sciences stock fell $1.75, or 3.9 percent, to $43 in recent action.
Human Genome Sciences is spending heavily to advance development of experimental compounds that are supposed treat everything from venous ulcers to immunodeficiency. The company said it has five experimental drugs in patient testing.
For the fourth quarter, Human Genome Sciences reported a net loss of $6 million, or 5 cents per share, compared to a net loss of $18 million, or 19 cents per share, in the 1999 fourth quarter. The loss was significantly below the 15 cents per share analysts had expected. The company said revenue surged to$5.3 million from $862,000 in the year-ago period.
Human Genome Sciences reported cash and short-term investments totaling $1.8 billion, including $12.3 million of restricted cash as of the end of 2000. This compares to $466.2 million, including $11.6 million of restricted cash, at the end of 1999.
"HGS ended 2000 with broader capabilities to discover and develop novel drugs than when the year began," William A. Haseltine, chairman and CEO, said in a statement
HGSI cuts loss, predicts higher R&D
By Ted Griffith, CBS.MarketWatch.com
Last Update: 12:24 PM ET Feb 15, 2001 NewsWatch
Latest headlines
Get Alerted
ROCKVILLE, Md. (CBS.MW) -- Human Genome Sciences narrowed its fourth-quarter net loss as revenue jumped from less than a million dollars to more than $5 million, the biotechnology company reported Thursday.
Today on CBS MarketWatch
Tech stocks steal the show
Ciena blows past profit forecast
Prudential cuts Amazon.com rating to 'sell'
February weakness roils Schwab
Due Diligence: Starbucks as coffee version of McDonald's?
More top stories...
CBS MarketWatch Columns
Updated:
2/15/2001 11:12:58 AM ET
But Human Genome Sciences also said it expects to post a significant loss this year as it ratchets up research and development spending by as much as 70 percent. The Rockville, Md.-based company said it anticipates a 2001 net loss of $70 million to $90 million, or 56 cents to 72 cents per share. Human Genome Sciences (HGSI: news, msgs) was expected to post a loss of 44 cents per share in 2001, according to the average estimate of analysts polled by First Call/Thomson Financial.
Human Genome Sciences stock fell $1.75, or 3.9 percent, to $43 in recent action.
Human Genome Sciences is spending heavily to advance development of experimental compounds that are supposed treat everything from venous ulcers to immunodeficiency. The company said it has five experimental drugs in patient testing.
For the fourth quarter, Human Genome Sciences reported a net loss of $6 million, or 5 cents per share, compared to a net loss of $18 million, or 19 cents per share, in the 1999 fourth quarter. The loss was significantly below the 15 cents per share analysts had expected. The company said revenue surged to$5.3 million from $862,000 in the year-ago period.
Human Genome Sciences reported cash and short-term investments totaling $1.8 billion, including $12.3 million of restricted cash as of the end of 2000. This compares to $466.2 million, including $11.6 million of restricted cash, at the end of 1999.
"HGS ended 2000 with broader capabilities to discover and develop novel drugs than when the year began," William A. Haseltine, chairman and CEO, said in a statement